Keytruda

Merck's Blockbuster Drug Wins Key New FDA Approval
Merck's Blockbuster Drug Wins Key New FDA Approval
Motley Fool
Merck
Keytruda
bladder cancer
NMIBC
Flag link:
US cancer death rate drops by sharpest rate on record
US cancer death rate drops by sharpest rate on record
BioPharma Dive
cancer
Bristol-Myers Squibb
Yervoy
Merck
Keytruda
Flag link:
Merck’s Keytruda Shows Mixed Results in Lung Cancer Study
Merck’s Keytruda Shows Mixed Results in Lung Cancer Study
BioSpace
Merck
Keytruda
small cell lung cancer
Flag link:
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Fierce Pharma
Merck
Keytruda
FDA
bladder cancer
NMIBC
Flag link:
Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors
Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors
Motley Fool
Merck
Keytruda
vaccines
China
Flag link:
Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Fierce Pharma
Keytruda
Merck
FDA
NMIBC
nadofaragene firadenovec
FerGene
gene therapy
Flag link:
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Pharmaceutical Business Review
Merck
Keytruda
bladder cancer
priority review
NMIBC
FDA
Flag link:
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst
Fierce Pharma
Merck
Keytruda
non-small cell lung cancer
Flag link:
Regeneron defends bid to challenge Merck in lung cancer
Regeneron defends bid to challenge Merck in lung cancer
Biopharma Dive
Regeneron
Libtayo
Merck
Keytruda
immuno-oncology
lung cancer
Flag link:
Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?
Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?
Motley Fool
Merck
Bristol-Myers Squibb
Yervoy
Opdivo
Keytruda
lung cancer
Flag link:
Bristol-Myers warns I-O blockbuster Opdivo will be 'under pressure' in 2020
Bristol-Myers warns I-O blockbuster Opdivo will be 'under pressure' in 2020
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Keytruda
Merck
Flag link:
Merck CFO: we’re not only about Keytruda
Merck CFO: we’re not only about Keytruda
PM Live
Merck
Keytruda
Flag link:
Merck beats estimates as Keytruda sales top $3 billion for first time
Merck beats estimates as Keytruda sales top $3 billion for first time
Yahoo/Reuters
Merck
Keytruda
earnings
Flag link:
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Pfizer
Eliquis
AbbVie
Humira
Flag link:
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Merck
Keytruda
China
non-small cell lung cancer
Flag link:
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
Flag link:
Merck, Pfizer execs explain how they tap sites for cancer trials
Merck, Pfizer execs explain how they tap sites for cancer trials
Biopharma Dive
cancer
clinical trials
Pfizer
Merck
immuno-oncology
Bavencio
Keytruda
Flag link:
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Flag link:
The top drugs facing cuts under Pelosi's pricing plan
The top drugs facing cuts under Pelosi's pricing plan
Biopharma Dive
drug pricing
Nancy Pelosi
regulatory
Revlimid
Keytruda
Opdivo
Januvia
insulin
Medicare
Flag link:
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Fierce Pharma
Merck
Keytruda
Eisai
Lenvima
endometrial cancer
Canada
Australia
Flag link:

Pages